Jerini AG Reports First Quarter Financial Results

Jerini AG (FSE:JI4) reported financial results for the first quarter ended March 31, 2007. Under International Financial Reporting Standards (IFRS), revenues for the three-month period increased by 11.1 percent to EUR 3.6 million from EUR 3.2 million for the same period in 2006, primarily attributable to revenues from a partnership agreement with Abbott. As of March 31, 2007, cash and cash equivalents amounted to EUR 61.7 million, compared to EUR 66.6 million at year end 2006. "Our financial position remains strong, and we plan to complete the US and European regulatory submissions for Icatibant in the treatment of hereditary angioedema (HAE) in the third quarter of this year. We are...

Want to see the full article?

• Purchase this article for only $3.00